BR112015023968A2 - Uso de um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de brachyury na preparação de uma composição imunoterapêutica para tratar ou prevenir cordoma, bem como composição assim preparada - Google Patents

Uso de um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de brachyury na preparação de uma composição imunoterapêutica para tratar ou prevenir cordoma, bem como composição assim preparada

Info

Publication number
BR112015023968A2
BR112015023968A2 BR112015023968A BR112015023968A BR112015023968A2 BR 112015023968 A2 BR112015023968 A2 BR 112015023968A2 BR 112015023968 A BR112015023968 A BR 112015023968A BR 112015023968 A BR112015023968 A BR 112015023968A BR 112015023968 A2 BR112015023968 A2 BR 112015023968A2
Authority
BR
Brazil
Prior art keywords
chordoma
antigen
yeast vehicle
treating
composition
Prior art date
Application number
BR112015023968A
Other languages
English (en)
Inventor
Apelian David
C Rodell Timothy
Palena Claudia
Schlom Jeffrey
Original Assignee
Globeimmune Inc
The Us Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, The Us Department Of Health And Human Services filed Critical Globeimmune Inc
Publication of BR112015023968A2 publication Critical patent/BR112015023968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

USO DE UM VEÍCULO DE LEVEDURA E UM ANTÍGENO DO CÂNCER COMPREENDENDO PELO MENOS UM ANTÍGENO DE BRACHYURY NA PREPARAÇÃO DE UMA COMPOSIÇÃO IMUNOTERAPÊUTICA PARA TRATAR OU PREVENIR CORDOMA, BEM COMO COMPOSIÇÃO ASSIM PREPARADA. Uma modalidade da invenção se refere a um método para tratar cordoma em um indivíduo que tem cordoma. O método inclui a etapa de administração a um indivíduo que tem cordoma, uma composição imunoterapêutica que compreende: (a) um veículo de levedura; e (b) um antígeno do câncer compreendendo pelo menos um antígeno de Brachyury. Outra modalidade da invenção se refere ao uso de uma composição imunoterapêutica compreendendo um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de Brachyury para cordoma em um indivíduo que tem cordoma. Ainda outra modalidade da invenção se refere ao uso de uma composição imunoterapêutica compreendendo um veículo de levedura.
BR112015023968A 2013-03-19 2014-03-19 Uso de um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de brachyury na preparação de uma composição imunoterapêutica para tratar ou prevenir cordoma, bem como composição assim preparada BR112015023968A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803332P 2013-03-19 2013-03-19
PCT/US2014/031183 WO2014186047A1 (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma

Publications (1)

Publication Number Publication Date
BR112015023968A2 true BR112015023968A2 (pt) 2017-08-22

Family

ID=51898771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023968A BR112015023968A2 (pt) 2013-03-19 2014-03-19 Uso de um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de brachyury na preparação de uma composição imunoterapêutica para tratar ou prevenir cordoma, bem como composição assim preparada

Country Status (15)

Country Link
US (2) US10507235B2 (pt)
EP (1) EP2976100B1 (pt)
JP (1) JP6509808B2 (pt)
KR (1) KR20150132867A (pt)
CN (1) CN105228646B (pt)
AU (1) AU2014265873B2 (pt)
BR (1) BR112015023968A2 (pt)
CA (1) CA2907560C (pt)
HK (1) HK1216861A1 (pt)
IL (1) IL241384B (pt)
MX (1) MX2015013380A (pt)
RU (1) RU2679806C2 (pt)
SG (2) SG10201707608QA (pt)
TW (2) TW201936206A (pt)
WO (1) WO2014186047A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3051449A1 (de) * 2015-01-29 2016-08-03 Bayer Technology Services GmbH Computerimplementiertes Verfahren zur Erstellung eines Fermentationsmodels
KR20180054587A (ko) * 2015-08-03 2018-05-24 글로브이뮨 변형된 효모-브라큐리 면역치료학적 조성물
AU2016302237B2 (en) * 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP1037643B1 (en) 1997-10-10 2003-12-03 Meyer Pharmaceuticals, LLC Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20060009404A1 (en) 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
BRPI0613025A2 (pt) 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW201412329A (zh) 2006-02-02 2014-04-01 Globeimmune Inc 用於誘發免疫反應之以酵母菌爲基礎之疫苗
MX2008012392A (es) 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.
CA2676783C (en) 2007-02-02 2016-04-05 Globeimmune, Inc. Improved methods for producing yeast-based vaccines
EP2444410A3 (en) * 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
JP5579451B2 (ja) 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR102019728B1 (ko) 2009-04-17 2019-09-09 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
ES2696551T3 (es) 2010-12-17 2019-01-16 Globeimmune Inc Composiciones y métodos para el tratamiento o la prevención de la infección por adenovirus-36 humano
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
US9579377B2 (en) 2011-06-14 2017-02-28 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
KR20180054587A (ko) 2015-08-03 2018-05-24 글로브이뮨 변형된 효모-브라큐리 면역치료학적 조성물

Also Published As

Publication number Publication date
AU2014265873A1 (en) 2015-10-22
AU2014265873B2 (en) 2019-01-17
JP6509808B2 (ja) 2019-05-08
EP2976100B1 (en) 2020-07-01
CA2907560A1 (en) 2014-11-20
IL241384B (en) 2019-12-31
RU2679806C2 (ru) 2019-02-13
EP2976100A1 (en) 2016-01-27
WO2014186047A1 (en) 2014-11-20
TW201936206A (zh) 2019-09-16
KR20150132867A (ko) 2015-11-26
WO2014186047A8 (en) 2015-01-15
US10507235B2 (en) 2019-12-17
RU2015144511A (ru) 2017-05-03
SG10201707608QA (en) 2017-10-30
US20160271238A1 (en) 2016-09-22
TWI674108B (zh) 2019-10-11
IL241384A0 (en) 2015-11-30
US20200046818A1 (en) 2020-02-13
MX2015013380A (es) 2016-01-08
SG11201507328RA (en) 2015-10-29
TW201446261A (zh) 2014-12-16
CA2907560C (en) 2021-12-07
CN105228646B (zh) 2021-04-06
JP2016516081A (ja) 2016-06-02
CN105228646A (zh) 2016-01-06
EP2976100A4 (en) 2016-10-19
HK1216861A1 (zh) 2016-12-09

Similar Documents

Publication Publication Date Title
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
BR112016002233A2 (pt) composições de adoçante
CL2016000388A1 (es) Composicion de 6 arnm que codifican para 5t4 (tpbg, survivina (birc5), ny-eso-1 (ctag1b), mage-c1, mage-c2 y muc1 y vacuna para fabricar un medicamento util para tratar cancer de pulmon
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
BR112017001725A2 (pt) tratamento de esclerose lateral amiotrófica
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015030543B8 (pt) Preparação para aplicação tópica para o tratamento da pele e infecções da mucosa
MX370723B (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía.
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
BR112016023729A2 (pt) espelho de veículo e método para a fabricação de tal espelho
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.